Fulltext

Real-world data reveal unmet clinical needs in insulin treatment in Asian people with type 2 diabetes: the Joint Asia Diabetes Evaluation (JADE) Register

Kong APS 1 , Lew T 2 , Lau ESH 1 , Lim LL 1 , Kesavadev J 3 , Jia W 4 Show all authors , Sheu WH 5 , Sobrepena L 6 , Tan ATB 7 , Nguyen TK 8 , Yoon KH 9 , Wang K 10 , Kodiappan K 11 , Treuer T 12 , Chan JCN 1 , JADE Collaborative Study Group

Affiliations 

  • 1 Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China
  • 2 Eli Lilly and Company (Taiwan) Inc., Taipei, Taiwan
  • 3 Jothydev's Diabetes and Research Centre, Kerala, India
  • 4 Shanghai Sixth People's Hospital, Shanghai, China
  • 5 Taichung Veterans General Hospital, Taichung, Taiwan
  • 6 Heart of Jesus Hospital, San Jose City, Philippines
  • 7 Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 8 MEDIC Medical Centre, Ho Chi Minh City, Vietnam
  • 9 St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, South Korea
  • 10 Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China
  • 11 Eli Lilly and Company, Kuala Lumpur, Malaysia
  • 12 Lilly Hungaria Kft, Budapest, Hungary
Diabetes Obes Metab, 2020 04;22(4):669-679.
PMID: 31903728 DOI: 10.1111/dom.13950

Abstract

AIMS: To explore the pattern of insulin use and glycaemic control in Asian people with type 2 diabetes, stratified by gender, young-onset diabetes (YOD; diagnosed before age 40 years), and diabetic kidney disease (DKD; estimated glomerular filtration rate [eGFR] 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications